INTERNATIONAL PATENT: TAKEDA PHARMACEUTICAL COMPANY LIMITED, BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM FILES APPLICATION FOR "DOSING REGIMEN FOR CD19 CAR NK CELLS IN TREATING CANCER"

GENEVA, Aug. 18 -- TAKEDA PHARMACEUTICAL COMPANY LIMITED (1-1, Doshomachi 4-chomeChuo-kuOsaka-shi, Osaka 541-8645), BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (210 West 7th StreetAustin, Texas 78701) filed a patent application (PCT/IB2025/051308) for "DOSING REGIMEN FOR CD19 CAR NK CELLS IN TREATING CANCER" on Feb 07, 2025. With publication no. WO/2025/169136, the details related to the patent application was published on Aug 14, 2025.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): SELLNER, Leopold (c/o Takeda Pharmaceuticals International AGThurgauerstrasse 1308152 Glattpark-Opfikon ZH), R...